Competitor Analysis Antibody Therapy of Inflammatory and Autoimmune Diseases
Product description
The present Competitive Intelligence Report about Antibody Therapy of Inflammatory and Autoimmune Diseases provides a competitor evaluation in the field of antibody therapeutics used or being developed for treatment of rheumatoid arthritis, psoriasis, Crohn’s disease, ulcerative colitis, multiple sclerosis, asthma and other autoimmune diseases as of December 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Inflammatory and autoimmune diseases are one of the major indication areas for the use of therapeutic antibodies. The commercial success of anti-TNF antibodies highlights the broad applicability of inflammatory targets to develop antibody therapeutics. Sales of anti-inflammatory and anti-autoimmune antibodies in 2009 exceeded US$ 21 bln. Inflammatory diseases with significant commercial potential as demonstrated by approvals of antibody therapeutics are rheumatoid arthritis and related diseases (psoriatic arthritis, ankylosing spondylitis, juvenile arthritis), psoriasis, Crohn’s disease and ulcerative colitis, but also multiple sclerosis and asthma. Rare indications such as paroxysmal nocturnal hemoglubinuria turned out to be attractive markets for anti-inflammatory antibody therapy. Among the emerging indications for anti-inflammatory antibody therapy are systemic lupus erythematosus. The rare autoimmune diseases benefit from antibodies approved for lead indications in follow-up programs, at least for clinical evaluation.
The report includes a compilation of currently active projects in research and development of antibody therapeutic for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of anti-inflammatory and anti-autoimmune antibodies. Competitor projects are listed in a tabular format providing information on:
Index
1. Antibody Therapy of Asthma
2. Antibody Therapy of Psoriasis
Psoriasis
Other inflammatory skin diseases
3. Antibody Therapy of Gastrointestinal Diseases
Crohn?s disease
Ulcerative colitis
Inflammatory bowel disease (IBD)
Other inflammatory GI diseases
4. Antibody Therapy of Multiple Sclerosis
Multiple sclerosis
Sciatic neuritis
5. Antibody Therapy of Rheumatoid Diseases
Rheumatoid arthritis
Systemic juvenile idiopathic arthritis
Psoriatic arthritis
Ankylosyng spondylitis
6. Antibody Therapy of Autoimmune Diseases
Systemic Lupus Erythematosus (SLE)
Type 1 diabetes
Sjogren’s Syndrome
Scleroderma
Dermatomyositis / Polymyositis
Cryopyrin-Associated Periodic Syndromes (CAPS), Muckle-Wells Syndrome, Familial Cold Autoinflammatory Syndrome (FCAS)
Behcet’s Disease
Vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis; Churg Strauss Syndrome, Polyarteritis Nodosa, Giant Cell Arteritis, Takayasu Arteritis)
Myasthenia gravis
Idiopathic/autoimmune/immune thrombocytopenic purpura
Corporate Anti-Inflammatory and Anti-Autoimmune Antibodies R&D Pipelines
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The present Competitive Intelligence Report about Antibody Therapy of Inflammatory and Autoimmune Diseases provides a competitor evaluation in the field of antibody therapeutics used or being developed for treatment of rheumatoid arthritis, psoriasis, Crohn’s disease, ulcerative colitis, multiple sclerosis, asthma and other autoimmune diseases as of December 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Inflammatory and autoimmune diseases are one of the major indication areas for the use of therapeutic antibodies. The commercial success of anti-TNF antibodies highlights the broad applicability of inflammatory targets to develop antibody therapeutics. Sales of anti-inflammatory and anti-autoimmune antibodies in 2009 exceeded US$ 21 bln. Inflammatory diseases with significant commercial potential as demonstrated by approvals of antibody therapeutics are rheumatoid arthritis and related diseases (psoriatic arthritis, ankylosing spondylitis, juvenile arthritis), psoriasis, Crohn’s disease and ulcerative colitis, but also multiple sclerosis and asthma. Rare indications such as paroxysmal nocturnal hemoglubinuria turned out to be attractive markets for anti-inflammatory antibody therapy. Among the emerging indications for anti-inflammatory antibody therapy are systemic lupus erythematosus. The rare autoimmune diseases benefit from antibodies approved for lead indications in follow-up programs, at least for clinical evaluation.
The report includes a compilation of currently active projects in research and development of antibody therapeutic for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of anti-inflammatory and anti-autoimmune antibodies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index
1. Antibody Therapy of Asthma
2. Antibody Therapy of Psoriasis
Psoriasis
Other inflammatory skin diseases
3. Antibody Therapy of Gastrointestinal Diseases
Crohn?s disease
Ulcerative colitis
Inflammatory bowel disease (IBD)
Other inflammatory GI diseases
4. Antibody Therapy of Multiple Sclerosis
Multiple sclerosis
Sciatic neuritis
5. Antibody Therapy of Rheumatoid Diseases
Rheumatoid arthritis
Systemic juvenile idiopathic arthritis
Psoriatic arthritis
Ankylosyng spondylitis
6. Antibody Therapy of Autoimmune Diseases
Systemic Lupus Erythematosus (SLE)
Type 1 diabetes
Sjogren’s Syndrome
Scleroderma
Dermatomyositis / Polymyositis
Cryopyrin-Associated Periodic Syndromes (CAPS), Muckle-Wells Syndrome, Familial Cold Autoinflammatory Syndrome (FCAS)
Behcet’s Disease
Vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis; Churg Strauss Syndrome, Polyarteritis Nodosa, Giant Cell Arteritis, Takayasu Arteritis)
Myasthenia gravis
Idiopathic/autoimmune/immune thrombocytopenic purpura
Corporate Anti-Inflammatory and Anti-Autoimmune Antibodies R&D Pipelines
- Abbott
- AbGenomics
- Ablynx
- Acorda Therapeutics
- Affimed Therapeutics
- Alder Biopharmaceuticals
- Alexion Pharmaceuticals
- Amgen
- Anthera Pharmaceuticals
- Apexigen
- Argos Therapeutics
- Astellas Pharma
- AstraZeneca
- Avaxia Biologics
- Bayer Schering Pharma
- Bio Mabs
- Bio Products Laboratory
- Biocon
- Biogen Idec
- BioLex
- Biotest
- BioTie Therapies
- Biovitrum
- BioWa
- Boehringer Ingelheim
- Boryung
- Bristol-Myers Squibb
- Celltrion
- Celgene
- Centocor (J&J)
- Cephalon
- Ception Therapeutics
- Cipla
- Cornerstone Therapeutics
- Compugen
- Dream Pharma
- Eisai
- Elan
- Emergent Biosolutions
- EMS
- Epistem
- Femta Pharmaceuticals
- Genaera
- Genentech
- Genexine
- Genmab
- Genzyme
- GlaxoSmithKline (GSK)
- Glenmark Pharmaceuticals
- Green Cross
- Hadasit Bio-Holdings
- Hospira
- Human Genome Sciences (HGS)
- Hunter Immunology
- iCo Therapeutics
- Immunomedics
- InNexus Biotechnology
- Inotek Pharmaceuticals
- Japan Tobacco
- Kaketsuken
- KaloBios Pharmaceuticals
- Kyowa Hakko Kirin Pharma
- LG Life Science
- Ligand Pharmaceuticals
- Lilly
- Mab Pharm
- MacroGenics
- MaimoniDex
- Merck & Co.
- Micromet
- Miltenyi Biotec
- Mitsubishi Tanabe Pharma
- Morphosys
- MRC Technology
- NasVax
- Nycomed
- Novartis
- NovImmune
- Novo Nordisk
- Otsuka Pharmaceuticals
- PanGenetics
- PDL BioPharma
- Pfizer
- Protalix Biotherapeutics
- Regeneron
- Roche
- Sanofi-Aventis
- Santen
- Seikagaku
- Selexys Pharmaceuticals
- Shanghai Biomabs Pharmaceuticals
- Shanghai C Guojian Pharmaceutical
- Shenyang Sunshine Pharmaceutical Corporation
- SK Chemicals
- Symphogen
- Takeda Pharmaceutical
- Talecris Biotherapeutics
- Taligen Therapeutics
- TcL Pharma
- Teijin
- Teva Pharmaceutical Industries
- Therapeutic Proteins Inc
- Tolerx
- Trillium Therapeutics
- UCB Pharma
- University of Viena
- Vaccinex
- XOMA
- Yuhan Co.
- Zenotech Laboratories
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
